Comparative Pharmacology
Head-to-head clinical analysis: NEOSTIGMINE METHYLSULFATE versus REGONOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSTIGMINE METHYLSULFATE versus REGONOL.
NEOSTIGMINE METHYLSULFATE vs REGONOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability and enhancing cholinergic transmission.
Regorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases involved in angiogenesis, oncogenesis, and tumor microenvironment, including VEGFR1-3, TIE2, PDGFR-β, FGFR1, KIT, RET, RAF-1, and BRAF.
0.5-2.5 mg intravenously or intramuscularly every 2-4 hours as needed for reversal of neuromuscular blockade or treatment of myasthenia gravis; for reversal of non-depolarizing neuromuscular blockade, 0.03-0.07 mg/kg intravenously with anticholinergic.
Intravenous: 400 mg every 12 hours for 60 doses. Maintenance: 400 mg twice daily for 180 days (6 months).
None Documented
None Documented
Terminal elimination half-life is approximately 0.7 to 1.2 hours (mean 0.8 h) in healthy adults. In renal impairment, half-life may be prolonged up to 3-4 hours, requiring dose adjustment.
Terminal half-life of 2–4 hours; clinically relevant for dosing every 6–8 hours in renal impairment.
Renal excretion of unchanged drug accounts for approximately 50% of elimination; the remainder is metabolized by microsomal enzymes and excreted in urine as metabolites. Biliary/fecal elimination is minimal (<5%).
Approximately 70% renal (unchanged) and 30% biliary/fecal as glucuronide conjugates.
Category A/B
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor